Your browser doesn't support javascript.
loading
Pharmacological effects of TAK-828F: an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease.
Igaki, Keiko; Nakamura, Yoshiki; Tanaka, Masayuki; Mizuno, Shinta; Yoshimatsu, Yusuke; Komoike, Yusaku; Uga, Keiko; Shibata, Akira; Imaichi, Hisashi; Takayuki, Satou; Ishimura, Yoshimasa; Yamasaki, Masashi; Kanai, Takanori; Tsukimi, Yasuhiro; Tsuchimori, Noboru.
Afiliação
  • Igaki K; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
  • Nakamura Y; Axcelead Drug Discovery Partners, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
  • Tanaka M; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
  • Mizuno S; Pharmaceutical Sciences, Takeda Pharmaceutical Company, Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
  • Yoshimatsu Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
  • Komoike Y; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Uga K; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Shibata A; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
  • Imaichi H; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
  • Takayuki S; Axcelead Drug Discovery Partners, Inc., 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
  • Ishimura Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
  • Yamasaki M; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
  • Kanai T; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
  • Tsukimi Y; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
  • Tsuchimori N; Pharmaceutical Research Division, Takeda Pharmaceutical Company, Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
Inflamm Res ; 68(6): 493-509, 2019 Jun.
Article em En | MEDLINE | ID: mdl-30972425
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucócitos Mononucleares / Doenças Inflamatórias Intestinais / Membro 3 do Grupo F da Subfamília 1 de Receptores Nucleares / Acetatos / Naftiridinas Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Inflamm Res Assunto da revista: ALERGIA E IMUNOLOGIA / PATOLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucócitos Mononucleares / Doenças Inflamatórias Intestinais / Membro 3 do Grupo F da Subfamília 1 de Receptores Nucleares / Acetatos / Naftiridinas Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Inflamm Res Assunto da revista: ALERGIA E IMUNOLOGIA / PATOLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão